Animals,
Год журнала:
2024,
Номер
14(2), С. 282 - 282
Опубликована: Янв. 16, 2024
Canine
atopic
dermatitis
(CAD)
is
a
genetically
predisposed
inflammatory
pruritic
skin
disease.
The
available
treatments
for
CAD
have
several
adverse
effects
and
vary
in
efficacy,
indicating
the
need
development
of
improved
treatments.
In
this
study,
we
aimed
to
elucidate
therapeutic
allogeneic
xenogeneic
exosomes
on
CAD.
Six
laboratory
beagle
dogs
with
were
randomly
assigned
three
treatment
groups:
control,
canine
exosome
(cExos),
or
human
(hExos)
groups.
Dogs
cExos
hExos
groups
intravenously
administered
1.5
mL
(5
×
1010)
(7.5
1011)
solutions,
respectively,
while
those
control
group
normal
saline
times
per
week
4
weeks.
Skin
lesion
score
transepidermal
water
loss
decreased
compared
group.
serum
levels
cytokines
(interferon-γ,
interleukin-2,
interleukin-4,
interleukin-12,
interleukin-13,
interleukin-31)
but
increased
anti-inflammatory
(interleukin-10
transforming
growth
factor-β),
immunomodulatory
effect
exosomes.
microbiome
analysis
revealed
that
alleviated
bacterial
dysbiosis.
These
results
suggest
therapy
may
alleviate
dogs.
Extracellular Vesicle,
Год журнала:
2023,
Номер
2, С. 100029 - 100029
Опубликована: Сен. 30, 2023
Extracellular
vesicles
(EVs)
are
lipid-bilayer
delimited
membrane
structures
released
by
cells,
and
play
a
role
in
intercell
communication
disease
development.
The
Global
market
for
EVs
diagnostic
therapeutic
applications
is
expanding.
This
review
maps
the
current
status
of
EV
industry,
summarizes
recent
advances
manufacturing,
focuses
on
preclinical
research
involving
EVs.
complexity
heterogeneity
provide
new
opportunities
development
clinical-grade
products.
standardization
manufacturing
robust
quality
control
must
meet
all
Food
Drug
Administration
requirements
expectations.
We
believe
evolution
their
mass
production
with
stringency
will
open
era
EV-based
products
near
future.
Bioconjugate Chemistry,
Год журнала:
2023,
Номер
34(7), С. 1177 - 1197
Опубликована: Июль 11, 2023
Short
interfering
RNAs
(siRNA)
are
a
powerful
class
of
genetic
medicines
whose
clinical
translation
can
be
hindered
by
their
suboptimal
delivery
properties
in
vivo.
Here,
we
provide
clinically
focused
overview
that
summarizes
ongoing
siRNA
trials
from
the
perspective
innovations
nonviral
strategies.
More
specifically,
our
review
begins
highlighting
barriers
and
physiochemical
make
it
challenging
to
deliver
We
then
commentary
on
specific
strategies,
including
sequence
modification,
ligand
conjugation,
nanoparticle
exosomal
packaging,
each
which
used
control
therapies
living
systems.
Last,
summary
table
also
highlights
indication
use,
target,
National
Clinical
Trial
(NCT)
number
associated
with
entry.
In
writing
this
review,
work
aims
highlight
key
challenges
strategies
for
effective
vivo,
while
simultaneously
summarizing
information
therapy
humans.
Abstract
In
recent
decades,
research
on
Extracellular
Vesicles
(EVs)
has
gained
prominence
in
the
life
sciences
due
to
their
critical
roles
both
health
and
disease
states,
offering
promising
applications
diagnosis,
drug
delivery,
therapy.
However,
inherent
heterogeneity
complex
origins
pose
significant
challenges
preparation,
analysis,
subsequent
clinical
application.
This
review
is
structured
provide
an
overview
of
biogenesis,
composition,
various
sources
EVs,
thereby
laying
groundwork
for
a
detailed
discussion
contemporary
techniques
preparation
analysis.
Particular
focus
given
state‐of‐the‐art
technologies
that
employ
microfluidic
non‐microfluidic
platforms
EV
processing.
Furthermore,
this
discourse
extends
into
innovative
approaches
incorporate
artificial
intelligence
cutting‐edge
electrochemical
sensors,
with
particular
emphasis
single
proposes
current
outlines
prospective
avenues
future
research.
The
objective
motivate
researchers
innovate
expand
methods
analysis
fully
unlocking
biomedical
potential.
Frontiers in Cell and Developmental Biology,
Год журнала:
2024,
Номер
12
Опубликована: Фев. 13, 2024
Exosomes,
extracellular
vesicles
secreted
by
cells,
have
garnered
significant
attention
in
recent
years
for
their
remarkable
therapeutic
potential.
These
nanoscale
carriers
can
be
harnessed
the
targeted
delivery
of
agents,
such
as
pharmaceuticals,
proteins,
and
nucleic
acids,
across
biological
barriers.
This
versatile
attribute
exosomes
is
a
promising
modality
precision
medicine
applications,
notably
realm
cancer
therapy.
However,
despite
substantial
potential,
still
confront
challenges
tied
to
standardization
scalability
that
impede
practice
clinical
applications.
Moreover,
heterogeneity
isolation
methodologies
limited
cargo
loading
mechanisms
pose
obstacles
ensuring
consistent
outcomes,
thereby
constraining
utility.
In
contrast,
exhibit
distinct
advantage
diagnosis,
they
harbor
specific
signatures
reflective
tumor's
genetic
proteomic
profile.
characteristic
endows
them
with
potential
serve
valuable
liquid
biopsies
non-invasive
real-time
monitoring,
making
possible
early
detection
development
personalized
treatment
strategies.
this
review,
we
provide
an
extensive
evaluation
advancements
exosome
research,
critically
examining
advantages
limitations
context
therapy
diagnosis.
Furthermore,
present
curated
overview
most
technological
innovations
utilizing
exosomes,
focus
on
enhancing
efficacy
detection.
Pharmaceutics,
Год журнала:
2024,
Номер
16(6), С. 709 - 709
Опубликована: Май 24, 2024
Of
all
the
numerous
nanosized
extracellular
vesicles
released
by
a
cell,
endosomal-originated
exosomes
are
increasingly
recognized
as
potential
therapeutics,
owing
to
their
inherent
stability,
low
immunogenicity,
and
targeted
delivery
capabilities.
This
review
critically
evaluates
transformative
of
exosome-based
modalities
across
pharmaceutical
precision
medicine
landscapes.
Because
precise
biomolecular
cargo
delivery,
posited
ideal
candidates
in
drug
enhancing
regenerative
strategies,
advancing
diagnostic
technologies.
Despite
significant
market
growth
projections
exosome
therapy,
its
utilization
is
encumbered
substantial
scientific
regulatory
challenges.
These
include
lack
universally
accepted
protocols
for
isolation
complexities
associated
with
navigating
environment,
particularly
guidelines
set
forth
U.S.
Food
Drug
Administration
(FDA).
presents
comprehensive
overview
current
research
trajectories
aimed
at
addressing
these
impediments
discusses
prospective
advancements
that
could
substantiate
clinical
translation
exosomal
therapies.
By
providing
analysis
both
capabilities
hurdles
therapeutic
applications,
this
article
aims
inform
direct
future
paradigms,
thereby
fostering
integration
systems
into
mainstream
practice.
Experimental & Molecular Medicine,
Год журнала:
2025,
Номер
unknown
Опубликована: Янв. 20, 2025
Abstract
Neuroinflammation,
a
significant
contributor
to
various
neurodegenerative
diseases,
is
strongly
associated
with
the
aging
process;
however,
date,
no
efficacious
treatments
for
neuroinflammation
have
been
developed.
In
aged
mouse
brains,
number
of
infiltrating
immune
cells
increases,
and
key
transcription
factor
increased
chemokine
levels
nuclear
kappa
B
(NF-κB).
Exosomes
are
potent
therapeutics
or
drug
delivery
vehicles
materials,
including
proteins
regulatory
genes,
target
cells.
present
study,
we
evaluated
therapeutic
efficacy
exosomes
loaded
nondegradable
form
IκB
(Exo-srIκB),
which
inhibits
translocation
NF-κB
suppress
age-related
neuroinflammation.
Single-cell
RNA
sequencing
revealed
that
these
anti-inflammatory
targeted
macrophages
microglia,
reducing
expression
inflammation-related
genes.
Treatment
Exo-srIκB
also
suppressed
interactions
between
macrophages/microglia
T
in
brain.
We
demonstrated
successfully
alleviates
by
primarily
targeting
activated
partially
modulating
functions
interferon-responsive
microglia
Thus,
our
findings
highlight
as
potential
agent
treating
